Finnish-Dutch biotech, a spin-off of Aalto and the University of Helsinki, developing therapies against drug-resistant bacterial infections.
| Date | Round | Amount |
|---|---|---|
| Sep 2025 | Seed Arivin Therapeutics closed a €3 million seed led by investor Michiel Seerden, with angels and non-dilutive funds from Business Finland, for its therapies against bacterial resistance. | $3.5M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.